|
US4221584A
(en)
*
|
1979-02-09 |
1980-09-09 |
Chevron Research Company |
Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides
|
|
US4735961A
(en)
|
1984-05-07 |
1988-04-05 |
Merck & Co., Inc. |
Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
|
|
ID18218A
(id)
*
|
1995-01-27 |
1998-03-19 |
Novo Nordisk As |
Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
|
|
JP4122056B2
(ja)
|
1995-04-06 |
2008-07-23 |
リジエネロン ファーマシューティカルズ，インコーポレイテッド |
Ｔｉｅ−２リガンド、その作製方法および使用方法
|
|
US20030040463A1
(en)
|
1996-04-05 |
2003-02-27 |
Wiegand Stanley J. |
TIE-2 ligands, methods of making and uses thereof
|
|
AU5154098A
(en)
|
1996-10-31 |
1998-05-22 |
Duke University |
Soluble tie2 receptor
|
|
US5919813C1
(en)
|
1998-03-13 |
2002-01-29 |
Univ Johns Hopkins Med |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
|
|
US5980929A
(en)
|
1998-03-13 |
1999-11-09 |
Johns Hopkins University, School Of Medicine |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
|
|
ATE241380T1
(de)
|
1999-03-26 |
2003-06-15 |
Regeneron Pharma |
Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
|
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
AU784231B2
(en)
|
2000-06-23 |
2006-02-23 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
|
|
WO2003034990A2
(en)
|
2001-10-25 |
2003-05-01 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
AU2003217274A1
(en)
|
2002-02-25 |
2003-09-09 |
Eli Lilly And Company |
Peroxisome proliferator activated receptor modulators
|
|
AU2003229627A1
(en)
|
2002-04-08 |
2003-10-20 |
Max-Planck-Gesellschaft Zur |
Ve-ptp as regulator of ve-cadherin mediated processes or disorders
|
|
WO2003090686A2
(en)
|
2002-04-25 |
2003-11-06 |
University Of Connecticut Health Center |
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
US6930117B2
(en)
|
2002-11-09 |
2005-08-16 |
The Procter & Gamble Company |
N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
|
|
US6946479B2
(en)
|
2002-11-09 |
2005-09-20 |
The Procter & Gamble Company |
N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
AU2005224091B2
(en)
|
2004-03-15 |
2012-02-02 |
Janssen Pharmaceutica, N.V. |
Novel compounds as opioid receptor modulators
|
|
WO2005089755A1
(en)
|
2004-03-18 |
2005-09-29 |
R-Tech Ueno, Ltd. |
Aqueous composition comprising thiazole derivative
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
SI1771474T1
(sl)
|
2004-07-20 |
2010-06-30 |
Genentech Inc |
Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
|
|
EP1819355A4
(en)
|
2004-09-28 |
2009-08-12 |
Genexel Sein Inc |
METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE
|
|
ZA200705695B
(en)
|
2004-12-21 |
2009-02-25 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
US7893040B2
(en)
|
2005-07-22 |
2011-02-22 |
Oculis Ehf |
Cyclodextrin nanotechnology for ophthalmic drug delivery
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
EP1962903B1
(en)
|
2005-12-15 |
2013-03-13 |
MedImmune Limited |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
|
|
RU2494108C2
(ru)
|
2006-04-07 |
2013-09-27 |
Аерпио Терапетикс, Инк. |
Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
ES2612258T3
(es)
|
2006-10-27 |
2017-05-16 |
Sunnybrook Health Sciences Center |
Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
US9403789B2
(en)
|
2008-02-21 |
2016-08-02 |
Sequoia Pharmaceuticals, Inc. |
Benzofuran-containing amino acid inhibitors of cytochrome P450
|
|
DK2385763T3
(en)
|
2009-01-12 |
2018-07-16 |
Aerpio Therapeutics Inc |
METHODS OF TREATING VASCULAR LEAK SYNDROME
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
AU2010221438C1
(en)
|
2009-03-03 |
2015-01-29 |
Alcon Research, Ltd. |
Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
|
|
US20100227905A1
(en)
|
2009-03-03 |
2010-09-09 |
Alcon Research, Ltd. |
Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
|
|
ES2726946T3
(es)
|
2009-07-06 |
2019-10-10 |
Aerpio Therapeutics Inc |
Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
RS54010B1
(sr)
|
2009-11-06 |
2015-10-30 |
Aerpio Therapeutics Inc. |
Inhibitori prolil hidroksilaze
|
|
US20110319455A1
(en)
*
|
2010-04-19 |
2011-12-29 |
Bruce Steven Klein |
Antifungal Treatment
|
|
ES2877629T3
(es)
|
2010-07-12 |
2021-11-17 |
Immunogenesis Inc |
Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
NZ610230A
(en)
|
2010-10-07 |
2015-07-31 |
Aerpio Therapeutics Inc |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
EP2647385A4
(en)
|
2010-12-02 |
2014-04-30 |
Maruzen Pharm Co Ltd |
TIE2 ACTIVATOR, VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (VEGF), ANTI-ANGIOGENESIS AGENT, MEANS FOR REINFORCING BLOOD VESSELS, MEANS FOR THE NORMALIZATION OF BLOOD VESSELS, DEVICES FOR STABILIZING BLOOD VESSELS AND PHARMACEUTICAL COMPOSITION
|
|
WO2013056240A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
BR112014008759A8
(pt)
|
2011-10-13 |
2017-09-12 |
Aerpio Therapeutics Inc |
Tratamento de doença ocular
|
|
US20130190324A1
(en)
|
2011-12-23 |
2013-07-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Topical ocular drug delivery
|
|
WO2013155512A2
(en)
|
2012-04-13 |
2013-10-17 |
The Johns Hopkins University |
Treatment of ischemic retinopathies
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
CA3012929C
(en)
|
2012-07-31 |
2023-01-17 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions for in vivo induction of pancreatic beta cell formation
|
|
WO2014056923A1
(en)
|
2012-10-11 |
2014-04-17 |
Ascendis Pharma Ophthalmology Division A/S |
Vegf neutralizing prodrugs for the treatment of ocular conditions
|
|
MX373894B
(es)
|
2012-11-08 |
2020-07-09 |
Clearside Biomedical Inc |
Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
|
|
EP2922572A1
(en)
|
2012-11-23 |
2015-09-30 |
AB Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
AU2014233363B2
(en)
|
2013-03-15 |
2017-06-29 |
EyePoint, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
CA2909080C
(en)
|
2013-04-11 |
2022-07-26 |
Sunnybrook Research Institute |
Methods, uses and compositions of tie2 agonists
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
US20160137717A1
(en)
|
2013-06-20 |
2016-05-19 |
Gabriela Burian |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
US20160151410A1
(en)
|
2013-07-02 |
2016-06-02 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
|
RU2676303C2
(ru)
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
EP3019526A1
(en)
|
2013-07-11 |
2016-05-18 |
Novartis AG |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
US9828422B2
(en)
|
2013-07-29 |
2017-11-28 |
Samsung Electronics Co., Ltd. |
Anti-Ang2 antibody
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
TR201905773T4
(tr)
|
2013-10-01 |
2019-05-21 |
Sphingotec Gmbh |
Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul.
|
|
CA2928852A1
(en)
|
2013-11-01 |
2015-05-07 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietin-based interventions for treating cerebral malaria
|
|
EP3116503A4
(en)
|
2014-03-14 |
2017-08-23 |
Aerpio Therapeutics, Inc. |
Hptp-beta inhibitors
|
|
WO2015152416A1
(ja)
|
2014-04-04 |
2015-10-08 |
国立大学法人東北大学 |
眼圧降下剤
|
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
WO2016049183A1
(en)
|
2014-09-24 |
2016-03-31 |
Aerpio Therapeutics, Inc. |
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
TWI806150B
(zh)
|
2014-11-07 |
2023-06-21 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|